首页 > 产品中心 > 抗体 > 药物对照抗体

Anti-Human IL-17A Reference Antibody (Secukinumab, RUO) (HS856026)

价格:
规格:
  • 100ug
  • 1mg
  • 5mg
  • 10mg
  • 25mg
  • 50mg
  • 100mg
数量:
  • 概述

  • 图片

  • 参考文献

  • 产品说明书

概述
货号HS856026
品牌abinScience
描述
Secukinumab (HS856026) is a research-grade recombinant antibody targeting CTLA-8. Produced in mammalian cells with native-like glycosylation.
Highlights
  • Research Grade — For PK/PD studies, assay development, and ADA research.
  • Native Glycosylation — Mammalian expression ensures native-like patterns.
种属反应性Human
应用ELISA, Bioactivity: FACS, Functional assay, Research in vivo
同种型IgG1-kappa
表达系统Mammalian cells
靶标CTLA-8, Cytotoxic T-lymphocyte-associated antigen 8, IL17, IL-17A, IL17A, CTLA8, IL-17, Interleukin-17A
内毒素水平< 10 EU/mg
纯度>95% purity as determined by SDS-PAGE.
纯化方式Protein A/G purified from cell culture supernatant.
Accession号Q16552
状态Liquid
保存溶液 0.01M PBS pH 7.4

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

产品使用信息
应用方法 稀释比例
ELISA 1:2000-1:20000
稳定性和存储Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
别名AIN457, 1229022-83-6
背景

Interleukin-17A (IL17A) is a ~17 kDa protein. Effector cytokine of innate and adaptive immune system involved in antimicrobial host defense and maintenance of tissue integrity. Signals via IL17RA-IL17RC heterodimeric receptor complex, triggering homotypic interaction of IL17RA and IL17RC chains with TRAF3IP2 adapter. This leads to downstream TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways ultimately resulting in transcriptional activation of cytokines, chemokines, antimicrobial peptides and matrix metalloproteinases, with potential strong immune inflammation. Plays an important role in connecting T cell-mediated adaptive immunity and acute inflammatory response to destroy extracellular bacteria and fungi. As a signature effector cytokine of T-helper 17 cells (Th17), primarily induces neutrophil activation and recruitment at infection and inflammatory sites. IL17A is the therapeutic target of secukinumab (Cosentyx).

1. Boisson, B. et al. (2013) Immunity 39, 676-86. PMID: 24120361
2. Kuestner, RE. et al. (2007) Journal of immunology (Baltimore, Md. : 1950) 179, 5462-73. PMID: 17911633
3. Wright, JF. et al. (2008) Journal of immunology (Baltimore, Md. : 1950) 181, 2799-805. PMID: 18684971
4. Liu, C. et al. (2009) Science signaling 2, ra63. PMID: 19825828
5. Puel, A. et al. (2011) Science (New York, N.Y.) 332, 65-8. PMID: 21350122
6. Fossiez, F. et al. (1996) The Journal of experimental medicine 183, 2593-603. PMID: 8676080
NoteFor research use only. Not suitable for clinical or therapeutic use.
Isotype ControlHuman IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507)
图片
  • SDS-PAGE

    SDS-PAGE for Research Grade Secukinumab.

  • SEC-HPLC

    SEC-HPLC detection for Research Grade Secukinumab.

  • Bioactivity

    Detects Human IL17A in indirect ELISAs.

参考文献
公式
质量 (g) = 浓度 (mol/L) × 体积 (L) × 分子量 (g/mol)
填写 质量、浓度、体积中的任意 2 项 + 分子量,自动计算未知值。
质量
=
浓度
×
体积
分子量 *
g/mol
公式
C₁ × V₁ = C₂ × V₂
填写 4 项中的任意 3 项,自动计算未知值。
母液
C₁ (起始浓度)
×
V₁ (起始体积)
=
工作液
C₂ (终浓度)
×
V₂ (终体积)

相关产品推荐